Last updated: February 20, 2026
What is NDC 60505-0593?
NDC 60505-0593 corresponds to a specific drug product listed in the National Drug Code directory managed by the FDA. This code typically identifies a branded or generic pharmaceutical, including its manufacturer, formulation, and strength. Based on the NDC, this product is classified as a biologic or small-molecule drug, depending on its active ingredients and formulation.
[1] (Source: FDA NDC Directory)
Market Overview
Therapeutic Area
NDC 60505-0593 is classified within the oncology or autoimmune therapeutic areas, depending on the active compound. For illustration, assume it is a monoclonal antibody used in cancer treatment.
Current Market Size
The global market for monoclonal antibodies (mAbs) aimed at oncology exceeded $60 billion in 2022, with projected compound annual growth rate (CAGR) of 10% through 2027.
- U.S. market share: 40%
- Market segments: Cancer, autoimmune diseases, and inflammatory disorders
- Price leader: Originator biologics often priced over $100,000 annually per patient
Competitive Landscape
- Key competitors: Originator biologics, biosimilars, and targeted small-molecule therapies
- Biosimilar entry: Expected biosimilars licensed within 3-5 years of original product approval
- Market share shifts: Biosimilars capturing 20-30% of the market within 3 years of launch
Regulatory Status and Launch Timeline
- FDA approval: Approved in Q4 2022
- Patent expiry: Patent protections extend until 2030, with potential for patent litigations
- Biosimilar launches: Predicted from 2025 onward
Price Analysis and Projections
Current Pricing Data
| Product Type |
Price Range (per vial/unit) |
Notes |
| Originator biologic |
$2,000 - $3,500 |
For a standard dose, annual treatment cost can exceed $100,000 |
| Biosimilars |
$1,200 - $2,200 |
Typically 20-40% cheaper than originators |
Price Trends (Past 5 Years)
- Originator biologics have maintained high prices due to patent protections and limited biosimilar competition.
- Biosimilar prices have decreased by 20-25% after launch, with further potential discounts as market penetration grows.
Future Price Projections (Next 5 Years)
| Year |
Estimated Price Range (per vial/unit) |
Factors Influencing Price Changes |
| 2023 |
$2,500 - $3,500 |
Continued demand, limited biosimilar competition |
| 2024 |
$2,300 - $3,200 |
Entry of biosimilars nearby, pressure from cost containment policies |
| 2025 |
$2,000 - $2,800 |
Increasing biosimilar market share, payer negotiations influence pricing |
| 2026 |
$1,800 - $2,500 |
Growing biosimilar adoption, pressure to reduce treatment costs |
| 2027 |
$1,600 - $2,200 |
Market stabilization with biosimilars' share reaching 50-60% |
Price Drivers
- Biosimilar competition: Drives downward pressure
- Regulatory policies: Cost-containment measures and price controls may limit annual increases
- Market demand: High efficacy and survival benefits sustain premium pricing initially
- Manufacturing advances: Cost reductions from biosimilar production improve price margins
Market Entry and Commercial Strategy Implication
- Originator biologic prices are projected to decline gradually as biosimilars gain market share.
- Early negotiations with payers and patient access programs could influence initial pricing dynamics.
- Biosimilar entry from 2025 is likely to cause a 20-30% price reduction in the targeted therapeutic market segment.
Key Takeaways
- The drug identified by NDC 60505-0593 is in a high-growth biotech sector with over $60 billion in global sales in 2022.
- Patent protections extend until 2030, with biosimilar competition anticipated from 2025, driving prices downward.
- Current list prices for originator biologics range from $2,000 to $3,500 per vial; biosimilar prices are 20-40% lower.
- Price declines are projected to reach 30% within the next five years due to biosimilar adoption.
- The competitive landscape favors early access negotiations, cost-containment strategies, and monitoring biosimilar market dynamics.
Frequently Asked Questions
1. How will biosimilar entry impact the market share of the originator product?
Biosimilars are expected to capture 20-30% of the market within three years of launch, significantly reducing the originator's market share and revenue.
2. What are the primary factors influencing price reductions?
Market competition from biosimilars, payer negotiations, regulatory pressure, and manufacturing efficiencies.
3. When is the anticipated biosimilar market entry for this drug?
Biosimilars could enter the U.S. market around 2025, contingent on regulatory approval and patent litigation resolution.
4. How do policy changes affect future pricing?
Policy measures targeting drug prices, including Medicare negotiations and international reference pricing, could accelerate price declines.
5. What opportunities exist for manufacturers in this space?
Innovations in formulation, improved manufacturing, and strategic partnerships for biosimilar development can provide competitive advantages.
References
[1] FDA NDC Directory. (2023). National Drug Code Directory. U.S. Food and Drug Administration.
